Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Revelation Biosciences, Inc. REVBW NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
49/100
2/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Revelation Biosciences, Inc. (REVBW) is a Biotechnology company in the Healthcare sector, currently trading at $0.01. It has a SharesGrow Score of 46/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Valuation: REVBW trades at a trailing Price-to-Earnings (P/E) of -0.9 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.04.

Net income is $9M (loss), growing at -4097.6%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $746,784 against $9M equity (Debt-to-Equity (D/E) ratio 0.08, conservative). Current ratio is 5.41 (strong liquidity). Debt-to-assets is 6.4%. Total assets: $12M.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future ?/100 (Fail), Income ?/100 (Fail).

REVBW SharesGrow Score Overview

61/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — REVBW

✓
VALUE Pass
100/100
REVBW trades at a trailing Price-to-Earnings (P/E) of -0.9 (S&P 500 average ~25). Forward PEG 0.04 — Peter Lynch undervalued (≤1.0). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
REVBW: +0%/yr revenue is, -4097.6%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet REVBW: Debt-to-Equity (D/E) ratio 0.08 (conservative), Current ratio is 5.41 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
REVBW: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.0079-0.0125
Volume2.76K
Avg Volume (30D)40.84K
Market Cap$53.32K
Beta (1Y)-0.17
Share Statistics
EPS (TTM)-23.95
Shares Outstanding$6.21M
Employees8
CEOJames Rolke
Financial Highlights & Ratios
Gross Profit$-27.06K
EBITDA$-9.04M
Net Income$-8.91M
Operating Income$-9.07M
Total Cash$10.7M
Total Debt$746.78K
Net Debt$-9.95M
Total Assets$11.58M
Price / Earnings (P/E)-0
Analyst Forecast
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS76135L1199

Price Chart

Track all markets on TradingView
REVBW
Revelation Biosciences, Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
0.01 52WK RANGE 0.01

People Also View

REVB
REVB
Revelation Biosciences, Inc.
$1.20
+0.84%
 JSPRW
JSPRW
Jasper Therapeutics, Inc.
$0.02
-20.19%
 SABSW
SABSW
SAB Biotherapeutics, Inc.
$0.03
-5.82%
 SRZNW
SRZNW
Surrozen, Inc.
$0.02
-7.43%
 ISPOW
ISPOW
Inspirato Incorporated
$0.01
+2.86%
 LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message